These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29674627)

  • 1. cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells.
    Majorini MT; Manenti G; Mano M; De Cecco L; Conti A; Pinciroli P; Fontanella E; Tagliabue E; Chiodoni C; Colombo MP; Delia D; Lecis D
    Cell Death Differ; 2018 Dec; 25(12):2147-2164. PubMed ID: 29674627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression.
    Paschall AV; Zimmerman MA; Torres CM; Yang D; Chen MR; Li X; Bieberich E; Bai A; Bielawski J; Bielawska A; Liu K
    BMC Cancer; 2014 Jan; 14():24. PubMed ID: 24422988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
    El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
    Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
    Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
    FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of synergistic drug combinations using breast cancer patient-derived xenografts.
    Turner TH; Alzubi MA; Harrell JC
    Sci Rep; 2020 Jan; 10(1):1493. PubMed ID: 32001757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1.
    Guo H; Treude F; Krämer OH; Lüscher B; Hartkamp J
    Sci Rep; 2019 Jun; 9(1):8755. PubMed ID: 31217499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition.
    Xia L; Zheng Z; Liu JY; Chen YJ; Ding J; Hu GS; Hu YH; Liu S; Luo WX; Xia NS; Liu W
    Cancer Immunol Res; 2021 Jun; 9(6):707-722. PubMed ID: 33875483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.
    Anborgh PH; Lee DJ; Stam PF; Tuck AB; Chambers AF
    Expert Opin Ther Targets; 2018 Aug; 22(8):727-734. PubMed ID: 30025479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibition of Histone Deacetylases Reverses Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through a Slug Mediated Mechanism].
    Rahimian A; Barati G; Mehrandish R; Mellati AA
    Mol Biol (Mosk); 2018; 52(3):474-481. PubMed ID: 29989579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics.
    Lee EW; Seong D; Seo J; Jeong M; Lee HK; Song J
    Cell Death Differ; 2015 Sep; 22(9):1463-76. PubMed ID: 25613375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.
    Boufraqech M; Zhang L; Nilubol N; Sadowski SM; Kotian S; Quezado M; Kebebew E
    Clin Cancer Res; 2016 Sep; 22(17):4491-504. PubMed ID: 27029493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metalloprotease-dependent activation of EGFR modulates CD44
    Wise R; Zolkiewska A
    Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.